粪菌移植改变肠易激综合征患者肠道菌群:一项随机双盲安慰剂对照研究结果
该随机双盲安慰剂对照研究纳入52例中重度肠易激综合征成人患者,随机接受粪菌移植或安慰剂胶囊12天并随访6个月。治疗3个月后,安慰剂组在IBS严重程度评分和IBS特异性生活质量上的改善均显著优于粪菌移植组;粪菌移植组粪便微生物多样性增加而安慰剂组未增加。作者认为改变肠道菌群不足以在IBS中获得临床改善,需不同研究设计和更大规模研究来检验粪菌移植在IBS中的作用。
要点
- 治疗3个月后,安慰剂组IBS-SSS评分改善显著优于粪菌移植组(p=0.012)。
- 治疗3个月后,安慰剂组IBS-QoL改善亦显著优于粪菌移植组(p=0.003)。
- 粪菌移植组粪便微生物多样性增加,而安慰剂组未增加。
核心结论
- 粪菌移植改变了肠易激综合征患者的肠道菌群,但安慰剂组在治疗3个月后的症状缓解优于粪菌移植组,改变肠道菌群不足以在IBS中获得临床改善。
- 作者认为需要不同研究设计和更大规模的研究来检验粪菌移植在IBS中的作用。
研究设计与样本
- 随机、双盲、安慰剂对照试验,纳入52例中重度肠易激综合征成人患者。
- 患者随机接受粪菌移植或安慰剂胶囊治疗12天,随访6个月。
- 在基线、1个月、3个月和6个月进行访视,使用IBS严重程度评分系统(IBS-SSS)和IBS特异性生活质量(IBS-QoL)评估症状,每次访视前采集粪便样本。
- 试验注册号:NCT02788071。
主要发现
- 治疗3个月后观察到IBS-SSS评分改善存在显著差异(p=0.012),有利于安慰剂组。
- 治疗3个月后IBS-QoL数据类似(p=0.003),有利于安慰剂组。
- 接受粪菌移植胶囊的患者粪便微生物多样性增加,而安慰剂组未增加。
局限性
- 作者指出需要不同研究设计和更大规模的研究来检验粪菌移植在IBS中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: IBS is associated with an intestinal dysbiosis and faecal microbiota transplantation (FMT) has been hypothesised to have a positive effect in patients with IBS. We performed a randomised, double-blind placebo-controlled trial to investigate if FMT resulted in an altered gut microbiota and improvement in clinical outcome in patients with IBS. DESIGN: We performed this study in 52 adult patients with moderate-to-severe IBS. At the screening visit, clinical history and symptoms were assessed and faecal samples were collected. Patients were randomised to FMT or placebo capsules for 12 days and followed for 6 months. Study visits were performed at baseline, 1, 3 and 6 months, where patients were asked to register their symptoms using the IBS-severity scoring system (IBS-SSS) and IBS-specific quality of life (IBS-QoL). Prior to each visit, faecal samples were collected. RESULTS: A significant difference in improvement in IBS-SSS score was observed 3 months after treatment (p=0.012) favouring placebo. This was similar for IBS-QoL data after 3 months (p=0.003) favouring placebo. Patients receiving FMT capsules had an increase in faecal microbial biodiversity while placebos did not. CONCLUSION: In this randomised double-blinded placebo-controlled study, we found that FMT changed gut microbiota in patients with IBS. But patients in the placebo group experienced greater symptom relief compared with the FMT group after 3 months. Altering the gut microbiota is not enough to obtain clinical improvement in IBS. However, different study designs and larger studies are required to examine the role of FMT in IBS. TRIAL REGISTRATION NUMBER: NCT02788071.
引用
- Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018. PMID: 29980607. doi:10.1136/gutjnl-2018-316434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。